SYMBYX is excited to be an active part of Australia’s innovative medical technology community, and recently closed their A-Round Funding raising more than $3 million (AUD) from a small group of highly credentialed investors, including Australian-based venture capital and global medical company founders. We thank them for sharing our vision of widespread use of laser light therapy in the treatment of diverse conditions, including Parkinson’s, Fibromyalgia, Bowel Disease and other gut-brain mediated indications.
Dr Markman, SYMBYX CEO, said “the Adelaide light therapy (photobiomodulation) trial showed laser therapy to be side-effect free, low cost and potentially clinically effective, with significant improvements in primary and secondary outcome measures for people living with Parkinsons. This is early stage but very promising testing which provides a clear impetus for additional higher-level trials. Australia boasts some incredible innovative scientists who are utilising light therapy across multiple neurodegenerative disorders and Parkinson’s is just the beginning. What sets SYMBYX apart simply from other technologies out there claiming effectiveness in this area is that our technology is premised on changing the human microbiome (the vast microbial colonies of bacterial and other gut species that play a vital role in mediating human health outcomes) as well as a full understanding of the gut-brain connection in chronic disease. Therefore SYMBYX is focused on two breakthrough or new frontiers – using innovative laser and light devices to reduce Parkinson’s symptoms – and understanding the role of the gut microbiome, and gut-brain connection, in other intractable issues including IBD or bowel disease, dementia, autism and sleep disorders.
Please be in touch with CEO, Wayne Markman, if you would like to be considered for an allocation in our next investment round expected next year in 2022. Email email@example.com